Your browser doesn't support javascript.
loading
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.
Saeed, Anwaar; Park, Robin; Dai, Junqiang; Al-Rajabi, Raed; Kasi, Anup; Baranda, Joaquina; Williamson, Stephen; Saeed, Azhar; Ripp, Jacob; Collins, Zachary; Mulvaney, Kelly; Shugrue, Molly; Firth-Braun, Jeanette; Godwin, Andrew K; Madan, Rashna; Phadnis, Milind; Sun, Weijing.
Affiliation
  • Saeed A; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsbur
  • Park R; Division of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
  • Dai J; Department of Biostatistics, Kansas University Medical Center, Kansas City, KS 66160, USA.
  • Al-Rajabi R; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA.
  • Kasi A; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA.
  • Baranda J; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA.
  • Williamson S; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA.
  • Saeed A; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.
  • Ripp J; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA.
  • Collins Z; Department of Radiology, Kansas University Medical Center, Kansas City, KS 66160, USA.
  • Mulvaney K; Kansas University Cancer Center, Kansas City, KS 66205, USA.
  • Shugrue M; Kansas University Cancer Center, Kansas City, KS 66205, USA.
  • Firth-Braun J; Kansas University Cancer Center, Kansas City, KS 66205, USA.
  • Godwin AK; Kansas University Cancer Center, Kansas City, KS 66205, USA; Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, KS 66160, USA.
  • Madan R; Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, KS 66160, USA.
  • Phadnis M; Department of Biostatistics, Kansas University Medical Center, Kansas City, KS 66160, USA.
  • Sun W; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA.
Cell Rep Med ; 4(2): 100916, 2023 02 21.
Article in En | MEDLINE | ID: mdl-36702123
ABSTRACT
This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable (pMMR/MSS) gastrointestinal malignancies including gastric/gastroesophageal junction/esophageal (G/GEJ/E) adenocarcinoma, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). Thirty-five patients are enrolled. There are no observed dose-limiting toxicities during dose escalation. The overall grade 3/4 treatment-related adverse event rate is 34%. Among evaluable patients (n = 30), the objective response rate (ORR) is 30%, disease control rate (DCR) 83.3%, 6-month progression-free survival (PFS) 36.7%, median PFS 4.5 months, and median overall survival (OS) 8.7 months. Responses are seen in 4 of 17, 3 of 10, and 2 of 3 patients with CRC, G/GEJ/E adenocarcinoma, and HCC, respectively. Participants with a PD-L1 combined positive score (CPS) ≥5 have numerically higher ORR, PFS, and OS. Cabozantinib plus durvalumab demonstrates a tolerable safety profile and potential efficacy in previously treated advanced pMMR/MSS gastrointestinal malignancies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Adenocarcinoma / Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Journal: Cell Rep Med Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Adenocarcinoma / Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Journal: Cell Rep Med Year: 2023 Document type: Article
...